Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective

Area of Science:

• Oncology
• Pharmacology
• Marine Biotechnology

Background:

• Trabectedin, a marine-derived chemotherapy, is FDA-approved for advanced soft tissue sarcoma (STS).
• It is particularly indicated for anthracycline-resistant liposarcoma and leiomyosarcoma (L-sarcomas).

Purpose of the Study:

• To evaluate the real-world safety and efficacy of trabectedin.
• To analyze a decade of clinical experience in a cohort of 86 patients with advanced STS.

Main Methods:

• Retrospective analysis of 86 patients treated with trabectedin over 10 years.
• Data collection included patient demographics, diagnoses (liposarcoma, leiomyosarcoma), treatment cycles, survival, and toxicity.
• Median follow-up and treatment cycles were recorded.

Main Results:

• The cohort comprised 46.51% liposarcoma and 43.02% leiomyosarcoma patients.
• Median overall survival was 13.5 months for the entire cohort.
• Trabectedin showed a favorable safety profile with 25% experiencing Grade 3+ toxicity (mostly myelosuppression) and no treatment-related deaths.

Conclusions:

• Trabectedin is a safe and effective option for advanced STS, including third- or fourth-line treatment.
• Real-world data support its use in patients with suboptimal performance status, demonstrating significant clinical benefit and survival.
• The drug's manageable safety profile contributes to its utility in challenging STS cases.